Novel vesicular and particulate drug delivery systems for topical treatment of acne

Expert Opinion on Drug Delivery

Volumn 5, Issue 6, 2008, Pages 665-679

  Castro, Gisele A ^a   Ferreira, Lucas A M ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Acne; Antiacne drugs; Liposomes; Polymeric microspheres; Solid lipid nanoparticles; Topical treatment

Indexed keywords

4 [3 (4 HYDROXYBUTYL) 4,4 DIMETHYL 2,5 DIOXO 1 IMIDAZOLIDINYL] 2 TRIFLUOROMETHYLBENZONITRILE; ADAPALENE; ANTI ACNE AGENT; ANTIANDROGEN; AZELAIC ACID; BENZOYL PEROXIDE; CHOLESTEROL; CLINDAMYCIN; CYPROTERONE ACETATE; DIANE; DIMYRISTOYLPHOSPHATIDYLCHOLINE; ERYTHROMYCIN; FINASTERIDE; ISOTRETINOIN; LIPOSOME; MICROSPHERE; NIOSOME; PHOSPHATIDYLCHOLINE; PLACEBO; POLYMETHACRYLIC ACID; POLYOXYETHYLENE OLEYL ETHER; POLYOXYETHYLENE STEARYL ETHER; POLYSTYRENE; RETINOIC ACID; RETINOID; SALICYLIC ACID; SOLID LIPID NANOPARTICLE; TAZAROTENE; TEA TREE OIL; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ACNE; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG PENETRATION; DRUG RETENTION; DRUG STABILITY; DRUG STORAGE; DRY SKIN; ENCAPSULATION; ERYTHEMA; HUMAN; MEDICAL LITERATURE; MICROENCAPSULATION; NONHUMAN; PATIENT COMPLIANCE; PROPIONIBACTERIUM ACNES; REVIEW; SEBACEOUS GLAND; SKIN ABRASION; SKIN BURNING SENSATION; SKIN IRRITATION; THERMOSTABILITY;

ACNE VULGARIS; ADMINISTRATION, TOPICAL; BENZOYL PEROXIDE; CLINDAMYCIN; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG STABILITY; HUMANS; IMIDAZOLES; LIPOSOMES; MICROSPHERES; NANOPARTICLES; NITRILES; TRETINOIN;

EID: 47349098243     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.5.6.665     Document Type: Review

References (99)

1. Fried RG, Wechesler A. Psychological problems in the acne patients. Dermatol Ther 2006;19:237-40
2. White GM. Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris. J Am Acad Dermatol 1998;39:S34-7
3. Zoubolis CC, Eady A, Philpott M, et al. What is the pathogenesis of acne? Exp Dermatol 2005;14:143-52
4. Gollnick H. Current concepts of the pathogenesis of acne. Drugs 2003;63(15):1579-96
5. Webster GF. Inflammation in acne vulgaris. J Am Acad Dermatol 1995;33(2):247-52
6. Koreck A, Pivarcsi A, Dobozy A, Kemény L. The role of innate immunity in the pathogenesis of acne. Dermatology 2003;206:96-105
7. Toyoda M, Nakamura M, Morohashi M. Neuropeptides and sebaceous glands. Eur J Dermatol 2002;12:422-7
8. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003;49(1 Suppl):S1-37
9. Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007;56:651-63.
10. Nyirady J, Grossman RM, Nighland M, et al. A comparative trial of two retinoids commonly used in the treatment of acne vulgaris. J Dermatolog Treat 2001;12:149-57
11. Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Cutis 2007;79(6 Suppl):9-25
12. Tanghetti E. The impact and importance of resistance. Cutis 2007;80(1 Suppl):5-9
13. Ellis CN, Millikan LE, Smith EB, et al. Comparison of adapalene 0.1% solution and tretinoin 0.025% gel in topical treatment of acne vulgaris. Br J Dermatol 1998;139(S52):41-7
14. Gollnick H, Schramm M. Topical drug treatment in acne. Dermatology 1998;196:119-25
15. Schäfer-Korting M, Korting HC, Ponce-Poschl E. Liposomal tretinoin for uncomplicated acne vulgaris. Clin Investig 1994;72:1086-91
16. Date AA, Naik B, Nagarsenker. Novel drug delivery systems: potential in improving topical delivery of antiacne agents. Skin Pharmacol Physiol 2006;19:2-16
17. Shalita AR, Chalker DK, Griffith RF, et al. Tazaroteno gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-bind, vehicle-controlled study. Cutis 1999;63:349-54
18. Patel VB, Misra A, Marfatia YS. Preparation and comparative clinical evaluation of liposomal gel of benzoyl peroxide for acne. Drug Dev Ind Pharm 2001;27:863-70
19. Leyden JJ. Topical treatment of acne vulgaris: retinoids and cutaneous irritation. J Am Acad Dermatol 1998;38:S1-4
20. Vogt A, Combadiere B, Hadam S, et al. 40nm, but not 750 or 1.500nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin. J Am Acad Dermatol 2006;126:1316-22
21. Vogt A, Mandt N, Landemann J, et al. Follicular targeting: a promising tool in selective dermatotherapy. J Investig Dermatol Symp Proc 2005;10:252-5
22. Mordon S, Sumian C, Devoisselle JM. Site-specific methylene blue delivery to pilosebaceous structures using highly porous nylon microspheres: an experimental evaluation. Lasers Surg Med 2003;33:119-25
23. Bernard E, Dubois JI, Wepierre J. Importance of sebaceous glands in cutaneous penetration of an antiandrogen: target effect of Liposomes. J Pharm Sci 1997;86:573-8
24. Lademann J, Richter H, Teichmann A, et al. Nanoparticles: an efficient carrier for drug delivery into hair follicle. Eur J Pharm Biopharm 2007;66:159-64
25. Rolland A, Wagner N, Chatelus A, et al. Site-specific drug delivery to pilosebaceous structures using polymeric microspheres. Pharm Res 1993;10:1738-44
26. Lasic DD. Novel applications of liposomes. Trends Biotechnol 1998;16:307-21
27. Touitou E, Junginger HE, Weiner ND, et al. Liposomes as carrier for topical and transdermal delivery. J Pharm Sci 1994;83:1189-203
28. Mezei M, Gulasekharam V. Liposomes: a selective drug delivery system for the topical route of administration. Lotion dosage form. Life Sci 1980;26:1473-7
29. Jung S, Otberg N, Thiede G, et al. Innovative liposomes as a transfollicular drug delivery system: penetration into porcine hair follicles. J Invest Dermatol 2006;126:1728-32
30. Lauer AC, Lieb LM, Ramachandran C, et al. Transfollicular drug delivery. Pharm Res 1995;12:179-86
31. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 2001;14:101-14
32. Cevc G, Blume G. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochim Biophys Acta 1992;1104:226-32
33. Uchegbu IF, Florence AT. Non-ionic surfactaint vesicles (niosomes): physical and pharmaceutical chemistry. Adv Coll Interf Sci 1995;58:1-55
34. Van Hal DA, Bouwstra JA, Rensen A, et al. Preparation and characterization of nonionic surfactant vesicles. J Coll Interf Sci 1996;178:263-73
35. Manconi M, Sinico C, Valenti D, et al. Niosomes as carriers for tretinoin. III: A study into the in vitro cutaneous delivery of vesicle-incorporated tretinoin. Int J Pharm 2006;311:11-9
36. Manconi M, Valenti D, Sinico C, et al. Niosomes as carriers for tretinoin. II: Influence of vesicular incorporation tretinoin photostability. Int J Pharm 2003;260:261-72
37. Manconi M, Valenti D, Sinico C, et al. Niosomes as carriers for tretinoin. I: Preparation and properties. Int J Pharm 2002;234:237-48
38. Johnson BA, Nunley JR. Topical therapy for acne vulgaris. How do you choose the best drug fbr each patient? Postgrad Med 2000;107:69-70, 73-76, 79-80
39. Skalko N, Cajkovac M, Jalenjack I. Liposomes with clindamicyn hydrochloride in the therapy of acne vulgaris. Int J Pharm 1992;85:97-101
40. Honzak L, Sentjurc M. Development of liposome encapsulated clindamycin for treatment of acne vulgaris. Pfügers Arch 2000;440(Suppl 5):R44-5
41. Raman A, Weir U, Bloofield SF. Antimicrobial effects of tea-tree oil its major components on Staphylococcus aureus, Staph. Epidermidis and Propionibacterium acnes. Lett Appl Microbiol 1995;21:242-5
42. Enshaieh S, Jooya A, Siadat AH, Iraji F. The efficacy of 5% topical tea tree oil gel in mild to moderate acne vulgaris: a randomized, double-blind placebo-controlled study. Indian J Dermatol Venereol Leprol 2007;73:22-5
43. Biju SS, Ahuja A, Khar RK. Tea tree oil concentration in follicular casts after topical delivery: determination by high-performance thin layer chromatography using a perfused bovine udder model. J Pharm Sci 2005;94:240-5
44. Lee HS, Kim IH. Salicylic acid peels for the treatment of acne vulgaris in Asian patients. Dermatol Surg 2003;29:1196-9
45. Hashimoto Y, Suga Y, Mizuno Y, et al. Salicylic acid peels in polyethylene glycol vehicle for the treatment of comedogenic acne in Japanese patients. Dermatol Surg 2008;34:276-9
46. Bhalerao SS, Raje H. Preparation, optimization, characterization and stability studies of salicylic acid liposomes. Drug Dev Ind Pharm 2003;29:451-67
47. Stewart ME, Downing DT, Cook JS, et al. Sebaceous gland activity and serum dehydroepiandrosterone sulfate levels in boys and girls. Arch Dermatol 1992;128:1345-8
48. Thiboutot D, Harris G, Iles V, et al. Activity of the type 1 5α-redutase exhibits regional differences in isolated sebaceous glands and whole skin. J Invest Dermatol 1995;105:209-14
49. Choudhry R, Hodgins MB, Van der Kwast TH, et al. Localization of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. Endocrinology 1992;133:467-75
50. Gruber DM, Sator MO, Joura EA, et al. Topical cyproterone acetate treatment in women with acne: a placebo-controlled trial. Arch Dermatol 1998;134:459-63
51. Tabbakhian M, Tavakoli N, Jaafari MR, Daneshamouz S. Enhancement of follicular delivery of finasteride by liposomes and niosomes. 1: In vitro permeation and in vivo deposition studies using hamster flank and ear models. Int J Pharm 2006;323:1-10
52. Kumar R, Singh B, Bakshi G, Karate OP. Development of liposomal systems of finasteride for topical applications: design, characterization, and in vitro evaluation. Pharm Dev Technol 2007;12:591-601
53. Battmann T, Bonfils A, Branche C, et al. RU 58841, a new specific topical antiandrogen: a candidate of choice for treatment of acne, androgenetic alopecia and hissutism. J Steroid Biochem Mol Biol 1994;48:55-60
54. Bernard E, Dubois JL, Wepierre J. Percutaneous absorption of a new antiandrogen included in liposomes or in solution. Int J Pharm 1995;126:235-43
55. Fulton JE Jr, Farzad-Bakshandeh A, Bradley S. Studies on the mechanism of action to topical peroxide and vitamin A acid in acne vulgaris. J Cutan Pathol 1974;1:191-200
56. Fluhr JW, Barsom O, Gehring W, Gloor M. Antibacterial efficacy of benzoyl peroxide in phospholipid liposomes. A vehicle-controlled, comparative study in patients with papulopustular acne. Dermatology 1999;198:273-7
57. Webster GF. Topical tretinoin in acne therapy. J Am Acad Dermatol 1998;39:S38-44
58. Lavker RM, Leyden JJ, Thorne EG. An ultrastructural study of the effects of topical tretinoin on microcomedones. Clin Ther 1994;14:773-80
59. Schaller M, Steinle R, Korting HC. Light and electron microscopic findings in human epidermis reconstructed in vitro upon topical application of liposomal tretinoin. Acta Derm Venereol 1997;77:122-6
60. Masini V, Bonte F, Meybeck A, Wepierre L. Cutaneous bioavailability in hairless rats of tretinoin in liposomes or gel. J Pharm Sci 1993;82:17-21
61. Patel VB, Misra A, Marfatia YS. Topical liposomal gel of tretinoin for the treatment of acne: research and clinical implications. Pharm Dev Technol 2000;5:455-64
62. Contreras MJF, Soriano MMJ, Diéguez AR. In vitro percutaneous absorption of all-trans retinoic acid applied in free form or encapsulated in stratum corneum lipid liposomes. Int J Pharm 2005;297:134-45
63. Sinico C, Manconi M, Peppi M, et al. Liposomes as carriers for dermal delivery of tretinoin: in vitro evaluation of drug permeation and vesicle-skin interaction. J Control Release 2005;103:123-36
64. Montenegro L, Panico AM, Ventimiglia A, Bonina FP. In vitro retinoic acid release and skin permeation from different liposome formulations. Int J Pharm 1996;133:89-96
65. Kitagawa S, Kasamaki M. Enhanced delivery of retinoic acid to skin by cationic liposomes. Chem Pharm Bull 2006;54:242-4
66. Patel VB, Misra A, Marfatia YS. Clinical assessment of the combination therapy with liposomal gels of tretinoin and benzoyl peroxide in acne. AAPS Pharm Sci Tech 2001;2:1-5
67. Brisaert M, Gabriëls M, Matthijs V. Plaizier-Vercammem. Liposomes with tretinoin: a physical and chemical evaluation. J Pharm Biomed Anal 2001;26:909-17
68. Ioele G, Cione E, Risoli A, et al. Accelerated photostability study of tretinoin and isotretinoin in liposome formulations. Int J Pharm 2005;293:251-60
69. Smith S, Morhenn V, Webster G. The characteristics and utility of solid phase porous microspheres: a review. J Drugs Dermatol 2006;5:969-74
70. Schaefer H, Watts F, Brod J, Illel B. Follicular penetration. In: Scott RC, Guy RH, Hadgraft J, editors, Prediction of percutancous penetration, methods, measurements, modeling. London: IBC Techincal Services; 1990. p. 163-73
71. Nacht S, Katz M. The Microsponge: a novel topical programmable delivery system. In: Osborne D, Amann A, editors, Topical drug delivery formulations. New York. Marcel Dekker; 1990. p. 299-35.
72. Sumian CC, Pitre FB, Gauthier BE, et al. A new method to improve penetration depth of dyes into follicular duct: potential application for laser hair removal. J Am Acad Dermatol 1999;41:172-5
73. Embil K, Nacht S. The Microsponge delivery system (MDS): a topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives. J Microencapsul 1996;13(5):575-88
74. Wester RC, Patel R, Nacht S, et al. Controlled release of benzoyl peroxide from a porous microsphere polymeric system can reduce topical irritancy. J Am Acad Dermatol 1991;24:720-6
75. Jelvehgari M, Siahi-Shadbad MR, Azarmi S, et al. The Microsponge delivery system of benzoyl peroxide: preparation, characterization and release studies. Int J Pharm 2006;308:124-32
76. Nokhodchi A, Jelvehgari M, Siahi MR, Mozafari MR. Factors affecting the morphology of benzoyl peroxide Microsponges. Micron 2007;38:834-40
77. Grove GL, Zerweck CR, Natch S, Leyden JJ. The effect of vehicle composition on the subjective and objective irritancy potential of retinoic acid formulations. Poster presentation at American Academy of Dermatology meeting; March 1997; San Francisco, United States
78. Leyden J, Grove G, Zerweck C. Facial tolerability of topical retinoid therapy. J Drugs Dermatol 2004;3:641-51
79. Nyirady J, Nighland M, Payonk G, et al. A comparative evaluation of tretinoin gel microsphere, 0.1%, versus tretinoin cream, 0.025%, in reducing facial shine. Cutis 2000;66:153-6
80. Galvin SA, Gilbert R, Baker M, et al. Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations. Br J Dermatol 1998;139(Suppl 52):34-40
81. Thiboutot D, Gold MH, Jarratt MT, et al. Randomized controlled trial of the tolerability, safety, and efficacy of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. Cutis 2001;68(Suppl 4):10-9
82. Dosik JS, Homer K, Arsonnaud S. Cumulative irritation potential of adapalene 0.1% cream and gel compared with tretinoin microsphere 0.04% and 0.1%. Cutis 2005;75:238-43
83. Berger R, Barba A, Fleischer A, et al. A double-blinded, randomized, vehicle-controlled, multicenter, parallel-group study to assess the safety and efficacy of tretinoin gel microsphere 0.04% in the treatment of acne vulgaris in adults. Cutis 2007;80:152-7
84. Nighland M, Yusuf M, Wisniewski S, et al. The effect of simulated solar UV irradiation on tretinoin in tretinoin gel microsphere 0.1% and tretinoin gel 0.025%. Cutis 2006;77:313-6
85. Nyirady J, Lucas C, Yusuf M, et al. The stability of tretinoin in tretinein gel microsphere 0.1%. Cutis 2002;70:295-8
86. Müller RH, Karsten M, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery: a review of the state of the art. Eur J Pharm Biopharm 2000;50:161-77
87. Dingler A, Gohla S. Production of solid lipid nanoparticles (SLN): scaling up feasibilities. J Microencapsul 2002;19:11-6
88. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004;56:1257-72
89. Mehnert W, Mäder K. Solid lipid nanoparticles production, characterization and applications. Adv Drug Deliv Rev 2001;47:165-96
90. Jenning V, Gysler A, Schäfer-Korting M, Gohla S. Vitamin A-loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur J Pharm Biopharm 2000;49:211-8
91. Liu J, Hu W, Chen H, et al. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int J Pharm 2007;328:191-5
92. Müster U, Nakamura C, Haberland A, et al. RU 58841-myristate-prodrug development for topical treatment of acne and androgenetic alopecia. Pharmazie 2005;60:8-12
93. Stecová J, Mehnert W, Blaschke T, et al. Cyproterone acetate loading to lipid nanoparticles for topical acne treatment: particle characterization and skin uptake. Pharm Res 2007;24:991-1000
94. Akman A, Durusoy C, Senturk M, et al. Treatment of acne with intermittent and conventional isotretinoin: a randomized, controlled multicenter study. Arch Dermatol Res 2007;299:467-73
95. Jenning V, Gohla S. Encapsulation of retinoids in solid lipid nanoparticles (SLN). J Microencapsul 2001;18:149-58
96. Lim Soo-Jeong, Kim Chong-Kook. Formulation parameters determining the physicochemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid. Int J Pharm 2002;243:135-46
97. Hu L, Tang X, Cui F. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J Pharm Pharmacol 2004;56:1527-35
98. Castro GA, Oréfice RL, Vilela JMC, et al. Development of a new solid lipid nanoparticle formulation containing retinoic acid for topical treatment of acne. J Microencapsul 2007;24:395-407
99. Sha KA, Date AA, Joshi MD, Patravale VB. Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. Int J Pharm 2007;345:163-71